4.6 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | intake_tier | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | GLP-1 Receptor Agonist Exposure Associated with 75% Lower Odds of Any Substance Use Disorder — All of Us Nested Case-Control Study | Tadesse M. Abegaz, Muktar Ahmed, Akshaya Srikanth Bhagavathula, Gabriel Frietze | https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1766770/full | 2026-03-10 | health | article | unprocessed | high |
|
research-task |
Content
Published in Frontiers in Psychiatry, March 10, 2026. DOI: 10.3389/fpsyt.2026.1766770
Study design: Retrospective nested case-control within the All of Us Research Program. Propensity score matched 1:1 (controlling for age, sex, race/ethnicity, diabetes/obesity status, oral hypoglycemic agent use). 90-day lag period for temporal sequencing. Observation window: January 2005–February 2025. GLP-1 RAs examined: liraglutide, semaglutide, exenatide, dulaglutide (combined exposure — no individual drug differentiation).
Sample sizes by SUD subtype:
- AUD cohort: n=22,652
- OUD cohort: n=13,226
- NUD (nicotine) cohort: n=42,320
- CUD (cocaine) cohort: n=9,296
Key effect sizes:
- Any SUD combined: OR = 0.25 (95% CI 0.22–0.30) — 75% lower odds
- AUD: OR = 0.26 (95% CI 0.20–0.34) — 74% lower odds
- OUD: OR = 0.31 (95% CI 0.23–0.42) — 69% lower odds
- NUD: OR = 0.32 (95% CI 0.27–0.39) — 68% lower odds
- CUD: OR = 0.25 (95% CI 0.16–0.40) — 75% lower odds
Key limitations: Observational — reverse causality possible despite 90-day lag. Combined GLP-1 exposure (individual drug effects not differentiated). Unmeasured confounding from psychiatric comorbidity, social support, healthcare-seeking behavior. No causal mechanism established.
Context in converging evidence: This is the third independent evidence stream for GLP-1 and SUD reduction:
- This study (All of Us, observational): OR=0.25, 75% lower odds — strongest effect size, weakest design
- Lancet Psychiatry Swedish cohort (within-individual, n=95,490): 47% SUD worsening reduction — strongest design for causal inference
- JAMA Psychiatry RCT (2025): 41% reduction in heavy drinking days, NNT 4.3 — gold standard design, AUD + obesity
Agent Notes
Why this matters: The convergence of three independent designs — with consistent direction despite different populations, methods, and outcome definitions — is the strongest pattern in the GLP-1 psychiatric evidence base. Even with observational limitations, OR=0.25 across four distinct substance categories (alcohol, opioid, nicotine, cocaine) is hard to explain as pure selection bias.
What surprised me: The cocaine use disorder effect size (OR=0.25) is as large as the alcohol effect. There is NO behavioral intervention that produces 75% reduction in cocaine use disorder odds. If this holds up to causal scrutiny, it would represent the largest treatment effect for CUD in the literature.
What I expected but didn't find: Individual GLP-1 drug differentiation (semaglutide vs. liraglutide vs. dulaglutide). The lack of drug-level analysis is a significant limitation given the mechanistic differences between GLP-1 agonists.
KB connections:
- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
- Connects to Session 34-35 findings on GLP-1 + AUD (NNT 4.3, JAMA Psychiatry 2025)
- Connects to Lancet Psychiatry Swedish cohort (Sessions 37-38) — third independent evidence stream
Extraction hints:
- Claim about GLP-1 reducing SUD odds across all substance categories — the cross-category breadth is the most distinctive feature
- The convergence across three designs is itself a meta-claim worth writing
- The cocaine use disorder effect size may be worth a specific claim given the absence of any comparable intervention
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history WHY ARCHIVED: Provides the largest observational evidence base for GLP-1 and SUD reduction — converges with within-individual Swedish study and JAMA Psychiatry RCT to form a three-design convergence pattern EXTRACTION HINT: Lead with the convergence pattern across three designs, not just this study — the extractor should write a claim that synthesizes all three evidence streams, then evaluate confidence based on their convergence